Scrip Interviews: GEXVal Focuses On Rare Diseases As It Builds On Ex-Takeda Assets
wpmaster
株式會社 GEXVal
June 4th, 2019
Scrip Interviews: GEXVal Focuses On Rare Diseases As It Builds On Ex-Takeda Assets
Shortly after GEXVal celebrated its first birthday, founder, president and CEO Dr. Juran Kato, gave her thoughts on a year in charge in an interview with leading international industry publication, Scrip. GEXVal were delighted to appear in the Scrip article and the opportunity to highlight their mission to bring new treatments to patients with rare diseases.
The interview describes how GEXVal came to spinout from Takeda in 2018; the company focus on repurposing and rare disease (pulmonary arterial hypertension and genetic neurodevelopmental disorders); pipeline assets and future plans.
Scrip:
https://pharmaintelligence.informa.com/products-and-services/news-and-insights/scrip
有關本事宜請諮詢：info@gexval.com
